Every Form 4 that Tela Bio, Inc. (TELA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow TELA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TELA filings page.
TELA Bio, Inc. (TELA) director and Chief Executive Officer Heather C. Getz reported purchasing 12,500 shares of common stock on 2026-08-17 in an open-market or private transaction at a weighted average price of $0.6649 per share, with individual trade prices ranging from $0.6504 to $0.6749. Following this purchase, she directly owns 532,500 shares of TELA common stock.
TELA Bio, Inc. director and Chief Executive Officer Heather C. Getz purchased 15,000 shares of common stock on 2026-08-14 in an open-market or private transaction. The weighted average purchase price was about $0.6978 per share, with individual trades between $0.697 and $0.6994. Following this transaction, she directly holds 520,000 shares of TELA Bio common stock.
TELA Bio, Inc. reports that Chief Executive Officer Heather C. Getz received new equity awards on August 3, 2026. She was granted 500,000 restricted stock units of common stock, increasing her holdings to 505,000 shares. She also received options for 1,365,000 shares at a $0.74 exercise price and 1,005,000 shares at $0.90, both expiring August 3, 2036. The RSUs vest in four equal annual installments beginning August 3, 2027, and each option vests 25% on that date with the remaining 75% vesting monthly over 36 months, subject to continued service.
Plovanic William J. reported acquisition or exercise transactions in this Form 4 filing.
TELA Bio, Inc. director William J. Plovanic received a grant of 20,930 shares of common stock, valued at $0.785 per share, as compensation. The shares were issued in lieu of cash under the company’s Amended and Restated Non-Employee Director Compensation Policy and are fully vested, bringing his direct holdings to 44,530 shares.
Capper Joseph H reported acquisition or exercise transactions in this Form 4 filing.
TELA Bio, Inc. director Joseph H. Capper received a grant of 6,227 shares of common stock on 2026-07-15. The shares were issued in lieu of cash compensation under the company’s Amended and Restated Non-Employee Director Compensation Policy and are fully vested. Following this grant, Capper directly owns 29,827 shares of TELA Bio common stock.
TELA Bio director Betty Jo Rocchio received new equity awards. She was granted 11,675 restricted stock units of common stock, increasing her direct common stock holdings to 23,600 shares after the award. These units vest on the earlier of June 9, 2027, the next annual stockholder meeting, or a Change in Control, subject to her continued service.
She also received a stock option covering 17,335 shares of common stock at an exercise price of $0.935 per share, expiring on June 9, 2036. This option vests on the same schedule and service conditions as the restricted stock units.
TELA Bio, Inc. director Joseph H. Capper reported receiving new equity awards in the form of common stock and stock options as compensation. On June 9, 2026 he was granted 11,675 and 11,925 restricted stock units, and options for 17,335 and 17,550 shares at an exercise price of $0.935 per share expiring on June 9, 2036.
The restricted stock units vest over time, either in three equal annual installments beginning on June 9, 2027 or on the earlier of June 9, 2027, the next annual stockholder meeting, or a Change in Control under the company’s 2019 equity plan, in each case requiring continued service. Following these grants, one line shows 23,600 common shares and another 11,925 common shares held directly.
TELA Bio director William J. Plovanic received new equity awards as part of his compensation. He was granted 11,675 shares of common stock and a stock option for 17,335 shares at an exercise price of $0.935 per share.
The stock units and the option both vest on the earlier of June 9, 2027, the next annual meeting of stockholders, or a Change in Control under TELA Bio’s Amended and Restated 2019 Equity Incentive Plan, in each case subject to his continued service. Following the grant, he directly owns 23,600 common shares and holds the new option for 17,335 underlying shares.
TELA Bio director Guido J. Neels reported equity awards rather than open-market trades. On June 9, 2026, he received two grants of Common Stock totaling 23,600 shares after the larger grant and 11,925 shares after the second grant, both at $0.00 per share as compensation awards.
He also received two stock option grants covering 17,335 and 17,550 shares of Common Stock at an exercise price of $0.935 per share, expiring on June 9, 2036. The footnotes state these restricted stock units and options vest over time, generally in annual or monthly installments beginning on or before June 9, 2027, or earlier upon specified events, subject to his continued service.
TELA Bio director Paul Thomas reported new equity awards. On June 9, 2026, he received two grants of Common Stock: 11,675 restricted stock units that vest in three equal annual installments starting June 9, 2027, and 11,925 restricted stock units that vest by the earlier of June 9, 2027, the next annual stockholder meeting, or a Change in Control, in each case subject to continued service.
He also received stock options for 17,335 and 17,550 shares of Common Stock at an exercise price of $0.935 per share, expiring on June 9, 2036. One option grant vests in 36 equal monthly installments beginning on June 9, 2026, and the other vests on the earlier of June 9, 2027, the next annual meeting, or a Change in Control, subject to continued service.
TELA Bio, Inc. director Guy P. Nohra reported compensation-related equity awards in the form of common stock and stock options. On June 9, 2026, he received 11,675 restricted stock units that vest in three equal annual installments beginning on June 9, 2027, and an additional 11,925 restricted stock units that vest on the earlier of June 9, 2027, the next annual meeting of stockholders, or a Change in Control, subject to continued service.
Following these awards, Nohra directly holds 23,600 shares of common stock from one grant and 11,925 shares from the other. He was also granted stock options for 17,335 and 17,550 shares of common stock at an exercise price of $0.935 per share, expiring on June 9, 2036. One option vests in 36 equal monthly installments starting June 9, 2026, and the other vests on the earlier of June 9, 2027, the next annual meeting, or a Change in Control, in each case conditioned on his continued service.
TELA Bio, Inc. director and CEO Antony Koblish reported a mix of equity awards and tax-related share dispositions. On February 20, 2026, he was granted 176,000 shares of common stock as restricted stock units that will vest in four equal annual installments beginning on February 20, 2027, subject to his continued service. He also received a stock option for 261,000 shares, vesting 25% on February 20, 2027 and the remaining 75% in equal monthly installments over the following 36 months, also subject to continued service. On February 21, 23, and 24, 2026, a total of 28,?? shares of common stock were disposed of at prices between $0.7174 and $0.7852 per share to cover withholding taxes upon RSU vesting, with shares withheld by the issuer rather than sold in open-market transactions.
TELA Bio, Inc. Chief Business Officer Gregory A. Firestone reported a mix of equity grants and tax-related share dispositions. On February 20, 2026, he was granted 55,000 stock options and 37,000 shares of common stock in the form of restricted stock units that vest in four equal annual installments beginning February 20, 2027, subject to his continued service. The option vests 25% on February 20, 2027, with the remaining 75% vesting in equal monthly installments over the next 36 months, also conditioned on continued service. On February 21 and 23, 2026, a total of 5,541 common shares were withheld by the company at prices of $0.7174 and $0.7660 per share to satisfy tax liabilities upon RSU vesting, leaving him with 139,307 common shares held directly, which includes 1,058 shares acquired under the employee stock purchase plan.
TELA Bio, Inc. reported several equity transactions by Chief Technology Officer Paul Talmo. On February 20, 2026, he received awards of 57,000 shares of common stock and 85,000 stock options, each at a grant price of $0.00 per share.
The stock award consists of restricted stock units that vest in four equal annual installments beginning on February 20, 2027, subject to continuous service. The option vests 25% on February 20, 2027, with the remaining 75% vesting in equal monthly installments over the following 36 months.
On February 21 and 23, 2026, the company withheld 3,385 and 4,061 shares of common stock, respectively, at prices of $0.7174 and $0.766 per share to cover tax liabilities upon RSU vesting. After these transactions, Talmo directly held 173,436 shares of common stock and 85,000 stock options.
TELA Bio, Inc. executive Roberto Cuca, the COO and CFO, reported a mix of equity awards and tax-related share withholdings. On February 20, 2026, he received a grant of 85,000 stock options and an award of 57,000 shares of common stock, both as direct ownership. The options vest over four years starting February 20, 2027, and the share award consists of RSUs vesting in four equal annual installments beginning the same date, subject to continued service.
To cover withholding taxes on RSU vesting, the issuer withheld 4,780 shares on February 21, 2026 at $0.7174 per share and 5,234 shares on February 23, 2026 at $0.7660 per share, characterized as tax-withholding dispositions rather than open-market sales. After these transactions, Cuca directly owned 257,377 shares of common stock.
TELA Bio, Inc. President Jeffrey Blizard reported equity awards consisting of stock options and restricted stock units granted on February 20, 2026. He was granted stock options for 127,000 shares at an exercise price of $0.00 per share and a separate award of 86,000 shares of common stock in the form of restricted stock units.
The restricted stock units will vest in four equal annual installments beginning on February 20, 2027, contingent on his continuous service through each vesting date. The stock option will vest 25% on February 20, 2027, with the remaining 75% vesting in equal monthly installments over the following 36 months, also subject to continued service.
TELA Bio, Inc. Chief Accounting Officer Megan Smeykal reported multiple equity transactions involving the company’s common stock. On February 18, 2026, she acquired 32,850 shares through a grant of restricted stock units (RSUs) at a stated price of $0.0000 per share. According to the footnotes, these RSUs vest in four equal annual installments beginning on February 18, 2027, contingent on her continued service.
On February 19, 21, and 23, 2026, shares of common stock were disposed of in three separate transactions coded “F,” each described as a tax-withholding disposition to satisfy withholding taxes upon RSU vesting. After the latest transaction, her direct holdings stood at 66,873 shares of common stock.
TELA Bio, Inc. reported an insider share purchase by major holders connected to EW Healthcare Partners. On 11/17/2025, these reporting persons acquired 3,604,000 shares of TELA Bio common stock in the company’s underwritten registered direct offering at a price of $1.11 per share. After this transaction, they beneficially own a total of 7,714,709 shares, split between EW Healthcare Partners Fund 2, L.P. and EW Healthcare Partners Fund 2-A, L.P. The filing notes that control over voting and investment decisions for these shares is held through the EW Healthcare general partner structure and its managers, who each disclaim ownership beyond their pecuniary interests.
TELA Bio (TELA) reported a director equity grant. On 10/31/2025, the reporting person acquired 11,925 shares of common stock at $0 (restricted stock units), bringing beneficial ownership of common stock to 11,925 shares, held directly.
The filing also shows a stock option for 17,550 shares at an exercise price of $1.23, expiring on 10/31/2035. The RSUs vest in three equal annual installments beginning 10/31/2026, and the option vests in 36 equal monthly installments starting 10/31/2025, in each case subject to continued service.
Reporting person: Betty Jo Rocchio, a director at TELA Bio, Inc. (TELA), reported securities awards received on 10/09/2025 and the filing was signed on 10/10/2025.
The report shows 11,925 restricted stock units (RSUs) granted with zero purchase price; these RSUs vest in three equal annual installments beginning on 10/09/2026, subject to continued service. The filing also reports a stock option to buy 17,550 shares with an exercise price of $1.48, granted on 10/09/2025, vesting monthly over 36 months and expiring on 10/09/2035.